title: Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics.
abstract: Mitochondrial metabolism greatly influences cancer cell survival, invasion, metastasis, and resistance to many anticancer drugs. Furthermore, molecular-targeted therapies (e.g., oncogenic kinase inhibitors) create a dependence of surviving cells on mitochondrial metabolism. For these reasons, inhibition of mitochondrial metabolism represents promising therapeutic pathways in cancer. This review provides an overview of mitochondrial metabolism in cancer and discusses the limitations of mitochondrial inhibition for cancer treatment. Finally, we present preclinical evidence that mitochondrial inhibition could be associated with oncogenic "drivers" inhibitors, which may lead to innovative drug combinations for improving the efficacy of molecular-targeted therapy.
authors.affiliation: Inserm UMR-S 1172, Faculté de Médecine, Université de Lille, 59045 Place Verdun Cedex, France ; Centre Hospitalier Régional et Universitaire (CHRU) de Lille, 5900 Lille, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Marchetti
authors.affiliation: Inserm UMR-S 1172, Faculté de Médecine, Université de Lille, 59045 Place Verdun Cedex, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Guerreschi
authors.affiliation: Centre Hospitalier Régional et Universitaire (CHRU) de Lille, 5900 Lille, France.
authors.forename: Laurent
authors.initials: L
authors.lastname: Mortier
authors.affiliation: Inserm UMR-S 1172, Faculté de Médecine, Université de Lille, 59045 Place Verdun Cedex, France.
authors.forename: Jerome
authors.initials: J
authors.lastname: Kluza